TELA TELA Bio, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1561921 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.5%
TTM net income YoY8.3%
TTM EPS YoY41.5%
Revenue 3-yr CAGR21.5%
Net income 3-yr CAGR—
Margins
Gross margin67.3%
Operating margin-41.8%
Net margin-49.3%
FCF margin-37.4%
EBITDA margin-41.1%
Returns
ROE-616.6%
ROA-54.2%
ROIC (approx.)-192.9%
Asset turnover1.10x
Leverage & solvency
Liabilities / assets107.4%
Debt / equity—
Current ratio3.61x
Interest coverage-5.56x
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $80.28M | $69.30M |
| Cost of revenue | $25.55M | $22.43M |
| Gross profit | $54.34M | $46.49M |
| R&D expense | $9.22M | $8.81M |
| SG&A expense | $15.69M | $14.72M |
| Operating income | -$33.76M | -$34.12M |
| Interest expense | $5.25M | $5.29M |
| Pretax income | -$38.60M | -$37.98M |
| Income tax | $230,000 | -$144,000 |
| Net income | -$38.83M | -$37.84M |
| EBITDA | -$33.12M | -$33.48M |
| EPS (basic) | -0.83 | -1.33 |
| EPS (diluted) | -0.83 | -1.33 |
| Weighted avg. shares (diluted) | 46.95M | 28.53M |
| Balance sheet | ||
| Cash & equivalents | $50.84M | $52.94M |
| Receivables | $10.35M | $10.10M |
| Inventory | $11.02M | $12.78M |
| Current assets | $75.58M | $78.07M |
| PP&E, net | $2.23M | $2.34M |
| Intangibles | $1.36M | $1.74M |
| Total assets | $81.42M | $86.57M |
| Current liabilities | $17.98M | $15.60M |
| Long-term debt | $55.65M | $41.12M |
| Total debt | $55.65M | $41.12M |
| Total liabilities | $75.11M | $58.11M |
| Shareholders' equity | $6.31M | $28.46M |
| Net debt | $4.81M | -$11.81M |
| Shares outstanding | 44.54M | 39.40M |
| Cash flow statement | ||
| Operating cash flow | -$28.22M | -$41.59M |
| Capital expenditure | $448,000 | $989,000 |
| Free cash flow | -$28.67M | -$42.58M |
| Investing cash flow | $846,000 | $4.45M |
| Financing cash flow | $25.75M | $43.06M |
| Depreciation & amortization | $630,000 | $632,000 |
| Stock-based compensation | $3.80M | $4.36M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.